Recently, a manuscript of the BeNeBio study protocol was published in BMC Trials. You might access the paper here: Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study.
Lisa Schots also presented the study protocol in a poster at the EADV Congress 2021.
